Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04489771
Title A Study of MK- 6482 in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

renal cell carcinoma

Therapies

Belzutifan

Age Groups: adult | senior
Covered Countries USA | BEL


No variant requirements are available.